StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Shares of NASDAQ CYCC opened at $1.99 on Tuesday. The company has a market cap of $19.89 million, a price-to-earnings ratio of -0.93 and a beta of 1.21. Cyclacel Pharmaceuticals has a 12-month low of $1.90 and a 12-month high of $7.95. The firm’s 50-day simple moving average is $3.14 and its 200 day simple moving average is $3.81.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) last announced its quarterly earnings data on Monday, March 28th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.17. During the same period in the prior year, the firm earned ($1.34) EPS. On average, research analysts predict that Cyclacel Pharmaceuticals will post -2.5 earnings per share for the current year.
About Cyclacel Pharmaceuticals (Get Rating)
Cyclacel Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.
- Get a free copy of the StockNews.com research report on Cyclacel Pharmaceuticals (CYCC)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.